JP2022542447A5 - - Google Patents
Info
- Publication number
- JP2022542447A5 JP2022542447A5 JP2022506467A JP2022506467A JP2022542447A5 JP 2022542447 A5 JP2022542447 A5 JP 2022542447A5 JP 2022506467 A JP2022506467 A JP 2022506467A JP 2022506467 A JP2022506467 A JP 2022506467A JP 2022542447 A5 JP2022542447 A5 JP 2022542447A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- residue corresponding
- acid residue
- hla class
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880501P | 2019-07-30 | 2019-07-30 | |
| US62/880,501 | 2019-07-30 | ||
| US202063029114P | 2020-05-22 | 2020-05-22 | |
| US63/029,114 | 2020-05-22 | ||
| PCT/IB2020/057173 WO2021019473A1 (en) | 2019-07-30 | 2020-07-29 | Mhc class ii molecules and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542447A JP2022542447A (ja) | 2022-10-03 |
| JP2022542447A5 true JP2022542447A5 (enExample) | 2023-08-08 |
| JP7811540B2 JP7811540B2 (ja) | 2026-02-05 |
Family
ID=74228599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506467A Active JP7811540B2 (ja) | 2019-07-30 | 2020-07-29 | Ｍｈｃクラスｉｉ分子及びその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12590139B2 (enExample) |
| EP (1) | EP4004034A4 (enExample) |
| JP (1) | JP7811540B2 (enExample) |
| KR (1) | KR20220052943A (enExample) |
| CN (1) | CN114450302A (enExample) |
| AU (1) | AU2020322246A1 (enExample) |
| BR (1) | BR112022001710A2 (enExample) |
| CA (1) | CA3146292A1 (enExample) |
| IL (1) | IL290223A (enExample) |
| MX (1) | MX2022001210A (enExample) |
| TW (1) | TW202116797A (enExample) |
| WO (1) | WO2021019473A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113795583B (zh) | 2019-03-04 | 2026-03-27 | 大学健康网络 | T细胞受体及其使用方法 |
| WO2021019475A1 (en) * | 2019-07-30 | 2021-02-04 | University Health Network | Mhc class ii molecules and methods of use thereof |
| CN118662607A (zh) * | 2023-03-15 | 2024-09-20 | 中国科学院上海巴斯德研究所 | 抑制过激炎性反应的蛋白及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0958834B1 (en) | 1996-11-13 | 2007-07-04 | Meiji Dairies Corporation | Use of peptide-based immunotherapeutic agent |
| IL157073A0 (en) | 2001-01-24 | 2004-02-08 | Harvard College | Therapeutic peptides for demyelinating conditions |
| GB0107628D0 (en) | 2001-03-27 | 2001-05-16 | Avidex Ltd | Substances |
| WO2003008450A1 (en) | 2001-06-12 | 2003-01-30 | Kyogo Itoh | Tumor antigen |
| US20080070835A1 (en) * | 2003-11-05 | 2008-03-20 | International Institute Of Cancer Immunology, Inc | Hla-Dr-Binding Antigen Peptide Derived From Wt1 |
| CN101001868A (zh) | 2004-06-17 | 2007-07-18 | 曼康公司 | 表位类似物 |
| US20060228758A1 (en) * | 2004-09-13 | 2006-10-12 | Xencor, Inc. | Analysis of MHC-peptide binding interactions |
| WO2006031883A2 (en) | 2004-09-13 | 2006-03-23 | Xencor, Inc. | Analysis of mhc-peptide binding interactions |
| US20100099090A1 (en) | 2007-03-05 | 2010-04-22 | Bristol-Mayers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2016135363A1 (es) | 2015-02-23 | 2016-09-01 | Servicio Andaluz De Salud | Método de obtención de datos útiles para predecir o pronosticar la transmisión vertical, la cronificación y/o el aclaramiento del virus de la hepatitis c |
| EP3337822A1 (en) | 2015-08-19 | 2018-06-27 | Rutgers, The State University of New Jersey | Novel methods of generating antibodies |
| CA3022227A1 (en) | 2016-04-27 | 2017-11-02 | University Health Network (Uhn) | Peptide-hla complexes and methods of producing same |
| CN111712254A (zh) | 2017-12-23 | 2020-09-25 | 鲁比厄斯治疗法股份有限公司 | 人工抗原呈递细胞和使用方法 |
| WO2021019476A1 (en) | 2019-07-30 | 2021-02-04 | University Health Network | Methods of identifying t cell receptors |
| WO2021019475A1 (en) | 2019-07-30 | 2021-02-04 | University Health Network | Mhc class ii molecules and methods of use thereof |
| WO2021019474A1 (en) | 2019-07-30 | 2021-02-04 | University Health Network | Mhc class ii molecules and methods of use thereof |
-
2020
- 2020-07-29 WO PCT/IB2020/057173 patent/WO2021019473A1/en not_active Ceased
- 2020-07-29 MX MX2022001210A patent/MX2022001210A/es unknown
- 2020-07-29 CN CN202080067823.XA patent/CN114450302A/zh active Pending
- 2020-07-29 TW TW109125665A patent/TW202116797A/zh unknown
- 2020-07-29 EP EP20848105.1A patent/EP4004034A4/en active Pending
- 2020-07-29 BR BR112022001710A patent/BR112022001710A2/pt unknown
- 2020-07-29 AU AU2020322246A patent/AU2020322246A1/en active Pending
- 2020-07-29 US US17/631,821 patent/US12590139B2/en active Active
- 2020-07-29 JP JP2022506467A patent/JP7811540B2/ja active Active
- 2020-07-29 KR KR1020227006943A patent/KR20220052943A/ko active Pending
- 2020-07-29 CA CA3146292A patent/CA3146292A1/en active Pending
-
2022
- 2022-01-30 IL IL290223A patent/IL290223A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7270001B2 (ja) | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ－ａ３を認識するｔ細胞受容体 | |
| JP2022542448A5 (enExample) | ||
| JP2022050400A (ja) | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 | |
| CN118994363A (zh) | 抗突变的kras的t细胞受体 | |
| EP3095792A1 (en) | T cell receptor with specificity for myeloperoxidase peptide and uses thereof | |
| JP2016531583A5 (enExample) | ||
| JP5936129B2 (ja) | ＲＥＩＣ／Ｄｋｋ−３タンパク質の部分領域ポリペプチド | |
| JP2018534255A5 (enExample) | ||
| CN116515765A (zh) | Cll1-car-t细胞及其制备方法与应用 | |
| CN108277205A (zh) | 表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途 | |
| CN113179631A (zh) | 通过临近使能反应疗法开发的共价蛋白质药物 | |
| JP2024509904A5 (enExample) | ||
| CN111892661A (zh) | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 | |
| CA3107859A1 (en) | Mr1 restricted t cell receptors for cancer immunotherapy | |
| Harrison et al. | Distribution and expression of CD44 isoforms and Ezrin during prostate cancer-endothelium interaction | |
| JP7811540B2 (ja) | Ｍｈｃクラスｉｉ分子及びその使用方法 | |
| CN116635427A (zh) | 嵌合抗原受体 | |
| AU2015346350A2 (en) | Anti-thyroglobulin t cell receptors | |
| IT202000006973A1 (it) | Antigeni herv tumore-specifici e loro uso nella immunoterapia del cancro | |
| US12594302B2 (en) | Single domain antibodies and their use in cancer therapies | |
| CN114891815A (zh) | Dna片段、表达载体、嵌合抗原受体t细胞、应用 | |
| TWI881991B (zh) | Ｉｉ類ｍｈｃ分子及其使用方法 | |
| CN108290940A (zh) | Tcr及其用途 | |
| AU2024311891A1 (en) | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy | |
| JP2024505111A (ja) | 改善された抗がん活性を有するｔ細胞の選択方法 |